Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795482 | 0.84 | SRD5A1 (0.40) | KMT2AMEN1ROCK1ALDH1A1NPC1 | |
| SCHEMBL795310 | 0.77 | HTR2C (0.48) | KMT2AMEN1HTR2CROCK1ALDH1A1 | |
| SCHEMBL4037805 | 0.75 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1MAPTCYP2C19 | |
| SCHEMBL10018239 | 0.74 | KMT2A (0.49) | KMT2AMEN1HTR2CROCK1ALDH1A1 | |
| SCHEMBL3016231 | 0.72 | ROCK1 (0.54) | KMT2AHTR2CROCK1ALDH1A1SIRT2 | |
| SCHEMBL15712664 | 0.72 | MEN1 (0.47) | KMT2AMEN1HTR2CROCK1ALDH1A1 | |
| SCHEMBL28405908 | 0.71 | SMN1; SMN2 (0.43) | KMT2AMEN1ALDH1A1MAPTCYP2C19 | |
| SCHEMBL25321827 | 0.71 | HTR2C (0.56) | HTR2CALDH1A1SIRT2MAPTMAPK1 | |
| SCHEMBL30475931 | 0.71 | HTR2C (0.56) | HTR2CALDH1A1SIRT2MAPTMAPK1 | |
| SCHEMBL20775025 | 0.70 | ROCK1 (0.43) | KMT2AMEN1HTR2CROCK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377961-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | LACRAMPE JEAN FERNAND ARMAND (FR) | 2012-03-22 | — | — | US | disclosed |
| US-8088795-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | KMT2A 1433/4885MEN1 1255/4885HTR2C 3108/4885 |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | KMT2A 1433/4885MEN1 1255/4885HTR2C 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.